^
Association details:
| Biomarker: | NECTIN4 expression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Padcev (enfortumab vedotin-ejfv) (Microtubule inhibitor, Nectin-4-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
Excerpt:
...Subjects must submit a tumor tissue for Nectin-4 expression....
Trial ID:
Source:
Title:
A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
Excerpt:
...- Subject must be able to submit a tumor tissue samples for Nectin-4 expression analysis at central laboratory....
Trial ID:
Less C2 evidence
Source:
Title:
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
Excerpt:
EV-101 is a phase I dose escalation/expansion study that enrolled patients with Nectin-4-expressing solid tumors (eg, metastatic urothelial carcinoma [mUC])...Among the 112 patients with mUC treated with single-agent EV 1.25 mg/kg, the investigator-assessed confirmed objective response rate (ORR) was 43%, and duration of response was 7.4 months.
DOI:
10.1200/JCO.19.02044
Trial ID:
Source:
Title:
Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin
Published date:
06/09/2021
Excerpt:
Sensitivity to EV is mediated by expression of NECTIN4, which is enriched in luminal subtypes of bladder cancer.
DOI:
10.1158/1078-0432.CCR-20-4175
